What are the changes in Annex 1?
The key changes in this new version include: quality management through the introduction of the contamination control strategy (CCS) concept combined with QRM and pharmaceutical quality system (PQS); introduction of new barrier technologies such as restricted access barrier systems (RABS) and isolators, which should be …
What is a contamination control strategy?
A contamination control strategy is a system that considers all the integral elements of pharmaceutical product manufacturing (1). This is best achieved using quality risk management principles and supporting risk assessments for contamination control and monitoring (detectability of contamination event) (2).
What is EU Annex 11?
Annex 11 is the FDA 21 CFR part 11 European equivalent. It is a guidance system for electronic records and electronic signatures in the pharmaceutical industry. The EU system applies to software, hardware, risk management and personal.
When will the EU Annex 1 be finalized?
The second targeted consultation period ended in July 2020 and the finalized version is anticipated by many to come in early 2021. Although Annex 1 was developed and is maintained by the EU, it is mandatory that U.S.-based manufacturers comply with these standards to sell products in Europe.
What is eueu GMP Annex 1?
EU GMP Annex 1 is the primary document governing the manufacture, control and release of sterile pharmaceutical products (both terminally sterilised and aseptically filled medicines). The Annex will shortly undergo a comprehensive update, as signalled by a new draft issued in February 2020.
What is Annex 1 of EudraLex?
Annex 1 of EudraLex “The Rules Governing Medicinal Products in the European Union” forms part of Volume 4 of the European guidelines covering the manufacture and release of sterile products, which are subject to special requirements (1). The Annex is going through a revision process, with the final version expected in 2020.
What is Annex 1 and why is it important?
Although Annex 1 was developed and is maintained by the EU, it is mandatory that U.S.-based manufacturers comply with these standards to sell products in Europe. Several international and U.S. organizations contributed to the Annex 1 revisions to ensure its global applicability, including WHO, PICS, FDA, ISPE, and PDA.
